Rofecoxib caused excess heart diseaseBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7485.212-a (Published 27 January 2005) Cite this as: BMJ 2005;330:212
- Susan Mayor
The COX 2 (cyclo-oxygenase-2) inhibitor rofecoxib (Vioxx) could have caused an estimated 88 000-140 000 excess cases of serious coronary heart disease in the United States since its launch in 1999, says a study published this week. The drug was withdrawn in September last year after being linked to increased cardiac deaths (BMJ 2004;329: 816).
The study analysed a cohort of all patients age 18-84 years receiving health care from a managed care organisation, Kaiser Permanente, in California, who were treated with …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial